Showing 1 - 6 results of 6 for search 'Kathy Gately', query time: 0.03s Refine Results
  1. 1
    Treatment Strategies for KRAS-Mutated Non-Small-Cell Lung Cancer

    Treatment Strategies for KRAS-Mutated Non-Small-Cell Lung Cancer by Éabha O’Sullivan, Anna Keogh, Brian Henderson, Stephen P. Finn, Steven G. Gray, Kathy Gately

    Published 2023-03-01
    Get full text
    Article
  2. 2
    Correction to: Vascular endothelial growth factor is an autocrine growth factor, signaling through neuropilin-1 in non-small cell lung cancer

    Correction to: Vascular endothelial growth factor is an autocrine growth factor, signaling through neuropilin-1 in non-small cell lung cancer by Martin P. Barr, Steven G. Gray, Kathy Gately, Emily Hams, Padraic G. Fallon, Anthony Mitchell Davies, Derek J. Richard, Graham P. Pidgeon, Kenneth J. O’Byrne

    Published 2020-01-01
    Get full text
    Article
  3. 3
    Dasatinib Treatment Increases Sensitivity to c-Met Inhibition in Triple-Negative Breast Cancer Cells

    Dasatinib Treatment Increases Sensitivity to c-Met Inhibition in Triple-Negative Breast Cancer Cells by Patricia Gaule, Nupur Mukherjee, Brendan Corkery, Alex J. Eustace, Kathy Gately, Sandra Roche, Robert O’Connor, Kenneth J. O’Byrne, Naomi Walsh, Michael J. Duffy, John Crown, Norma O’Donovan

    Published 2019-04-01
    Get full text
    Article
  4. 4
    Co-Targeting PIM Kinase and PI3K/mTOR in NSCLC

    Co-Targeting PIM Kinase and PI3K/mTOR in NSCLC by Gillian Moore, Clara Lightner, Samira Elbai, Lauren Brady, Siobhan Nicholson, Ronan Ryan, Katie E. O’Sullivan, Kenneth J. O’Byrne, Carmen Blanco-Aparicio, Sinead Cuffe, Michael O’Neill, Susan Heavey, Stephen P. Finn, Kathy Gately

    Published 2021-04-01
    Get full text
    Article
  5. 5
    Protein Tyrosine Phosphatase Non-Receptor 11 (<i>PTPN11</i>/Shp2) as a Driver Oncogene and a Novel Therapeutic Target in Non-Small Cell Lung Cancer (NSCLC)

    Protein Tyrosine Phosphatase Non-Receptor 11 (<i>PTPN11</i>/Shp2) as a Driver Oncogene and a Novel Therapeutic Target in Non-Small Cell Lung Cancer (NSCLC) by Cathy E. Richards, Yasir Y. Elamin, Aoife Carr, Kathy Gately, Shereen Rafee, Mattia Cremona, Emer Hanrahan, Robert Smyth, Daniel Ryan, Ross K. Morgan, Susan Kennedy, Lance Hudson, Joanna Fay, Kenneth O’Byrne, Bryan T. Hennessy, Sinead Toomey

    Published 2023-06-01
    Get full text
    Article
  6. 6
    Identification and clinical impact of potentially actionable somatic oncogenic mutations in solid tumor samples

    Identification and clinical impact of potentially actionable somatic oncogenic mutations in solid tumor samples by Sinead Toomey, Aoife Carr, Mateusz Janusz Mezynski, Yasir Elamin, Shereen Rafee, Mattia Cremona, Clare Morgan, Stephen Madden, Khairun I. Abdul-Jalil, Kathy Gately, Angela Farrelly, Elaine W. Kay, Susan Kennedy, Kenneth O’Byrne, Liam Grogan, Oscar Breathnach, Patrick G. Morris, Alexander J. Eustace, Joanna Fay, Robert Cummins, Anthony O’Grady, Roshni Kalachand, Norma O’Donovan, Fergal Kelleher, Aine O’Reilly, Mark Doherty, John Crown, Bryan T. Hennessy

    Published 2020-02-01
    Get full text
    Article

Search Tools: